Key result
The therapeutic response to clopidogrel is variable among patients with acute coronary syndrome, and incomplete platelet inhibition is associated with increased risk.
Answers are grounded in this paper and cite their sources.
Discusses the variability in therapeutic response to clopidogrel among patients with ACS, particularly in relation to reduced-function CYP2C19 genetic variants.
FFECTIVE PLATELET INHIBITION HAS BECOME A CORnerstone in the management of patients with acute coronary syndrome (ACS). The addition of clopidogrel to aspirin has provided significant reductions in major cardiovascular events in patients with ACS in general, and particularly among those treated invasively by percutaneous coronary intervention (PCI). 1 Yet studies have demonstrated that the therapeutic response of clopidogrel is variable among patients, 2 and low or incomplete platelet inhibition has been associated with increased risk
No takes yet. Share an insight, caveat, or question.
Fuster et al. (2010) conducted an editorial in Acute coronary syndrome (ACS). Clopidogrel and CYP2C19 genetic variant was evaluated. The therapeutic response to clopidogrel is variable among patients with acute coronary syndrome, and incomplete platelet inhibition is associated with increased risk.
Synapse has enriched 10 related papers. Consider them for comparative context: